Data processing: measuring – calibrating – or testing – Measurement system in a specific environment – Biological or biochemical
Reexamination Certificate
2005-10-13
2009-08-04
Brusca, John S (Department: 1631)
Data processing: measuring, calibrating, or testing
Measurement system in a specific environment
Biological or biochemical
C435S006120
Reexamination Certificate
active
07571055
ABSTRACT:
This document relates to methods and materials involved in diagnosing SLE. For example, this document relates to methods and materials involved in diagnosing SLE, diagnosing severe SLE, and assessing a mammal's susceptibility to develop severe SLE. For example, this document provides nucleic acid arrays that can be used to diagnose SLE in a mammal. Such arrays can allow clinicians to diagnose SLE based on a simultaneous determination of the expression levels of many genes that are differentially expressed in SLE patients as compared to healthy controls. In addition, methods and materials for assessing SLE activity, determining the likelihood of experiencing active SLE, and detecting SLE treatment effectiveness are provided herein.
REFERENCES:
patent: 5143854 (1992-09-01), Pirrung et al.
patent: 5744305 (1998-04-01), Fodor et al.
patent: 6905827 (2005-06-01), Wohlgemuth et al.
patent: 7118865 (2006-10-01), Behrens et al.
patent: 2003/0148298 (2003-08-01), O'Toole et al.
patent: 2004/0009479 (2004-01-01), Wohlgemuth et al.
patent: WO 00/22093 (2000-04-01), None
patent: WO 03/090694 (2000-11-01), None
patent: WO 02/057414 (2002-07-01), None
Alarcón et al., “Systemic Lupus Erythematosus in Three Ethnic Groups,”Arthritis Rheum., 1998, 41(7):1173-1180.
Arnett and Reveille, “Genetics of Systemic Lupus Erythematosus,”Rheum. Dis. Clin. N. Am., 1992, 18(4):865-892.
Asmal et al., “Production of Ribosome Components in Effector CD4+T Cells is Accelerated by TCR Stimulation and Coordinated by ERK-MAPK,”Immunity, 2003, 19:535-548.
Bae et al., “Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus,”Lupus, 2001, 10:405-409.
Baechler et al., “Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus,”Proc. Natl. Acad. Sci. USA, 2003, 100(5):2610-2615.
Baechler et al., “Expression levels for many genes in human peripheral blood cells are highly sensitive to ex vivo incubation,”Genes and Immunity, 2004, 5:347-353.
Balomenos et al., “Interferon-γ is Required for Lupus-like Disease and Lymphoaccumulation in MRL-lprMice,”J. Clin. Invest., 1998, 101(2):364-371.
Bennett et al., “Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood,”J. Exp. Med., 2003, 197(6):711-723.
Blanco et al., “Induction of Dendritic Cell Differentiation by IFN-α in Systemic Lupus Erythematosus,”Science, 2001, 294:1540-1543.
Bombardier et al., “Derivation of the SLEDAI. A Disease Activity Index for Lupus Patients,”Arthritis Rheum., 1992, 35(6):630-640.
Braun et al., “Type I Interferon controls the onset and severity of autoimmune manifestations inlprmice,”J. Autoimmun., 2003, 20:15-25.
Buttrum et al., “Changes in neutrophil rheology after acute ischemia and reperfusion in the rat hindlimb,”J. Lab. Clin. Med., 1996, 128(5):506-514.
Coleman, “Of mouse and man—what is the value of the mouse in predicting gene expression in humans?”Drug Discovery Today, 2003, 8(6):233-235.
de Veer et al., “Functional classification of interferon-stimulated genes identified using microarrays,”J. Leukocyte Biology, 2001, 69:912-920.
Der et al., “Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays,”Proc. Natl. Acad. Sci. USA, 1998, 95:15623-15628.
Dörner and Lipsky, “Correlation of circulating CD27highplasma cells and disease activity in systemic lupus erythematosus”Lupus, 2004, 13:283-289.
Eisen et al., “Cluster analysis and display of genome-wide expression patterns,”Proc. Natl. Acad. Sci. USA, 1998, 95:14863-14868.
Fukuyama et al., “Systemic Lupus Erythematosus After β-Interferon Therapy for Chronic Hepatitis C: A Case Report and Review of the Literature,”Am. J. Gastroenterol., 2000, 95(1):310-312.
Gergely, Jr. et al., “Persistent Mitochondrial Hyperpolarization, Increased Reactive Oxygen Intermediate Production, and Cytoplasmic Alkalinization Characterize Altered IL-10 Signaling in Patients with Systemic Lupus Erythematosus,”J. Immunol., 2002, 169:1092-1101.
Gibson, “Simulated evolution and artificial selection,”BioSystems, 1989, 23:219-229.
Ginsburg et al., “Circulating and pokeweed mitogen-induced immunoglobulin-secreting cells in systemic lupus erythematosus,”Clin. Exp. Immunol., 1979, 35:76-88.
Gladman et al., “The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus,”Arthritis Rheum., 1996, 39(3):363-369.
Gregersen and Brehrens, “Fine mapping the phenotype in autoimmune disease: the promise and pitfalls of DNA microarray technologies,”Genes and Immunity, 2003, 4:175-176.
Gu et al., “Analysis of inflammation related gene expression spectrum in ankylosing spondylitis patients using cDNA microarray,”Zhonghua Yi Xue Za Zhi, 2001, 81(17):1030-1034 (Abstract only—article is in Chinese).
Harada et al., “Identification of early plasma cells in peripheral blood and their clinical significance,”Br. J. Haematol., 1996, 92:184-191.
Hay et al., “The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus,”Q. J. Med., 1993, 86:447-458.
Hirano et al., “Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors,”Oncogene, 2000, 19:2548-2556.
Hochberg, “Updating the American College of Rheumatology Revised Criteria for the Classification of Systemic Lupus Erythematosus,”Arthritis&Rheumatism, 1997, 40(9):1725.
Jacob et al., “In Vivo Treatment of (NZB x NZW)FlLupus-Like Nephritis with Monoclonal Antibody to γ Interferon,”J. Exp. Med., 1987, 166:798-803.
Lau et al., “Further evidence of increased polymorphonuclear cell activity in patients with Raynaud's phenomenon,”Br. J. Rheumatol., 1992, 31:375-380.
Liang et al., “Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus,”Arthritis Rheum., 1989, 32(9):1107-1118.
Liossis et al., “Immune cell biochemical abnormalities in systemic lupus erythematosus,”Clin. Exp. Rheumatol., 1997, 15:677-684.
Liu et al., “Comparison of differentially expressed genes in T lymphocytes between autoimmune disease and murine models of autoimmune disease,”Clinical Immunology, 2004, 112:225-230.
Lövgren et al., “Induction of Interferon-α Production in Plasmacytoid Dendritic Cells by Immune Complexes Containing Nucleic Acid Released by Necrotic or Late Apoptotic Cells and Lupus IgG,”Arthritis Rheum., 2004, 50(6):1861-1872.
Pascual et al., “The central role of dendritic cells and interferon-α in SLE,”Curr. Opin. Rheumatol., 2003, 15:548-556.
Perl et al., “Mitochondrial hyperpolarization: a checkpoint of T-cell life, death and autoimmunity,”Trends Immunol., 2004, 25(7):360-367.
Petri et al., “Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study,”Arthritis Rheum., 1991, 34(8):937-944.
Rainen et al., “Stabilization of mRNA Expression in Whole Blood Samples,”Clin. Chem., 2002, 48(11):1883-1890.
Rascu et al., “Clinical Relevance of Fcγ Receptor Polymorphisms,”Ann. N.Y. Acad. Sci., 1997, 815:282-295.
Reimold et al., “Plasma cell differentiation requires the transcription factor XBP-1,”Nature, 2001, 412:300-307.
Richards et al., “Interferon-γ is required for lupus nephritis in mice treated with the hydro
Behrens Timothy W.
Gillespie Emily C.
Gregersen Peter K.
Brusca John S
Fish & Richardson P.C.
Regents of the University of Minnesota
The Feinstein Institute for Medical Research
LandOfFree
Systemic lupus erythematosus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Systemic lupus erythematosus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Systemic lupus erythematosus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4124157